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How can stenosis of one renal
artery cause failure of
two kidneys?
To the Editor: The suggestion that treating renal artery
stenosis of one kidney can prevent progressive renal fail-
ure of both kidneys is not new, but it remains biologically
implausible [1]. Who has ever seen a patient with uni-
lateral fibromuscular dysplasia and a serum creatinine of
400 lmol/L?
Korsakas et al [1] describe a cohort of 28 patients
with advanced renal failure and atheromatous renal
artery stenosis (ARAS). In the 17 patients with unilateral
ARAS, what was causing the progressive renal impair-
ment in the contralateral kidney, and how could revas-
cularization of the other kidney arrest this process? The
authors make two suggestions. Improved blood pressure
(BP) control after intervention could slow the progres-
sion of nephropathy, but there were no major changes
in BP in the study. Alternatively, the patients may have
had a “diffuse renal disease” and superimposed ARAS.
Clearly, this must have been the case in the unilateral
group, and if we have to postulate the existence of another
diffuse disease to explain the problem in one kidney, why
would it not be the culprit in the other? This diffuse dis-
ease is increasingly well recognized, and should perhaps
be called atherosclerotic nephropathy (AN) [2].
The hypothesis that best explains the results in this and
other studies in ARAS is that most hypertensive arteri-
opaths with chronic progressive renal failure have AN,
and quite a lot of them (because of the common predispo-
sitions) coincidentally have ARAS. AN causes progres-
sive nephron loss at a fairly uniform rate. ARAS can cause
a rise in serum creatinine because of underperfusion of
viable nephrons, reversible after revascularization. The
superimposition of these two conditions fits nicely with
the evident, but short-lived, improvement after revascu-
larization seen in this paper.
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Icodextrin-induced sterile
peritonitis: Neutrophil
activation and peritoneal
injury
To the Editor: I read with great interest the article by
Toure´ et al on comparison between icodextrin-induced
peritonitis (IP) and bacterial peritonitis (BP) [1]. They ex-
amined surface expression of several neutrophils recep-
tors and found that activated peritoneal-infiltrating neu-
trophils were distinct from resting circulating neutrophils
because of phenotypic changes. Their results showed a
smaller inflow of activated neutrophils in IP that in BP.
However, in IP, few neutrophils are identified, but
marked cellular infiltration of the connective tissue by
lymphocytes, eosinophils, and mast cells was identified
in the first peritoneal biopsy from a patient with a
typical symptomatology [2]. Immunoperoxidase stain-
ing demonstrated that the infiltrating cells were mostly
macrophages (CD68) and T lymphocytes (CD3) [2].
Mechanisms of activation of these cell populations should
thus be evaluated and compared too in IP and in BP in
further studies.
Toure´ et al suggest too that peritoneal injury was less
severe in IP than in BP. This affirmation is based on com-
parison between solute clearances and CA125 concen-
trations in IP and BP [1]. Despite this report, several
lines of evidence suggest that IP is not a benign event:
several manifestations of acute peritoneal inflammation,
including mesothelial inflammation and desquamation,
presence of fibrin clusters on the peritoneal surface, and
edema, varying degrees of peritoneal inflammation char-
acterized by venulitis, together with marked cellular
infiltration, were recently identified [2, 3]. These data
confirm the hypothesis that peritoneal inflammation of
the icodextrin-associated peritonitis is not so benign.
Further investigations are needed to determine the im-
pact of IP inflammatory lesions on the peritoneal mem-
brane longevity.
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Reply from the Authors
The purpose of our study was to compare icodextrin-
induced peritonitis (IP) to bacterial peritonitis (BP). Be-
cause tissue damage after acute bacterial infection results
from excessive neutrophil infiltration and activation in
the infected tissue [1], we analyzed peritoneal neutrophil
phenotype. We found that despite a burst of intraperi-
toneal cytokines, aseptic peritonitis is associated with a
small inflow of activated neutrophils. We think that the
low number of neutrophils and the poor reactive oxygen
species production by peritoneal-infiltrating neutrophils
may account for the weak peritoneal damage occurring
during acute IP. In addition, the differences in the phe-
notypic expressions of transmigrated neutrophils that we
observed between IP and BP indicate that inflammatory
stimuli that activate neutrophils in both type of peritoni-
tis are clearly distinct. Indeed, positive intradermal skin
tests, high amounts of peritoneal cytokines, and predomi-
nance of peritoneal monocytes observed during IP argue
for a delayed-type hypersensitivity reaction. This is con-
sistent with the histologic examination of the peritoneal
biopsy obtained from a patient with IP described by
Goffin et al.
We agree with Dr. Tintillier that icodextrin-induced
peritonitis is not a benign event. Bacterial peritonitis also
is not a benign event. Our data just show that acute peri-
toneal injury is less severe during IP than BP. This result
does not mean that IP is a gentle disease. The peritoneal-
damaging potential of peritonitis is normally limited by
elimination of the primary event that initiates inflamma-
tory reaction. Persistence of the inflammatory insult may
lead to severe peritoneal injury. In the cases reported
by Goffin et al, icodextrin was not withdrawn despite
several episodes of cloudy dialysate. We think that the
major risk of peritoneal injury during IP is that it goes
unrecognized.
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7-84 PTH lowers bone
turnover and explains why the
1-84 PTH/7-84 PTH ratio
predicts bone turnover
To the Editor: In this journal’s October 2001 is-
sue, Monier-Faugere et al [1] demonstrated the clinical
significance of circulating large C-terminal parathyroid
hormone (PTH) fragments; PTH-(1-84)/large C-PTH
fragment ratio was superior to total PTH in predicting
bone turnover state in humans. They found predomi-
nance of PTH-(1-84) relative to large C-PTH fragment
predicts high bone turnover, whereas predominance of
large C-PTH fragment relative to PTH-(1-84) predicts
low bone turnover, regardless of total PTH levels. This
work’s significance has been obscured by erroneous in-
terpretations of a recent Endocrinology publication by
Langub et al, in which ∼18.5× the amount of human
C-PTH-(7-84) fragment was used to antagonize human
PTH-(1-84) in thyroparathyroidectomized rats [2]. In
contrast, only a slight excess of large C-PTH fragment
relative to PTH-(1-84) was associated with low bone
turnover per Monier-Faugere et al. The Monier-Faugere
et al study suggests 2-fold excesses of large C-PTH frag-
ment effectively antagonize full-length PTH. However,
because the antagonistic activities of human PTH-(7-84)
relative to human PTH-(1-84) was assessed in rats [2],
relative potencies of these peptides for the corresponding
human receptors cannot be ascertained from the Langub
et al study. Differences in key residues can dramati-
cally affect affinity of a ligand for a particular receptor.
Given cross-species receptor pharmacology differences,
the absolute or relative concentrations of the fragment
and full-length peptide in Langub et al are not relevant
from a clinical perspective. Rather, those findings sup-
port the Monier-Faugere et al study, demonstrating that
the PTH-(1-84)/PTH-(7-84) ratio is more clinically infor-
mative than standard total PTH assays.
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